On May 6, 2025, D. Boral Capital analyst Jason Kolbert announced that he has maintained both his rating and price target for Cormedix (CRMD, Financial). The analyst continues to rate the stock as a "Buy," mirroring his previous assessment.
The price target for Cormedix (CRMD, Financial) has been maintained at $15.00 USD. There is no change in the price target from the prior evaluation, indicating steady confidence in the stock's potential.
Investors keen on Cormedix (CRMD, Financial) should note that the current rating and price target remain consistent with past analyses by Jason Kolbert, providing a stable outlook for the company's stock performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Cormedix Inc (CRMD, Financial) is $15.50 with a high estimate of $19.00 and a low estimate of $12.00. The average target implies an upside of 46.99% from the current price of $10.55. More detailed estimate data can be found on the Cormedix Inc (CRMD) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Cormedix Inc's (CRMD, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Cormedix Inc (CRMD, Financial) in one year is $1809.38, suggesting a upside of 17058.65% from the current price of $10.545. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cormedix Inc (CRMD) Summary page.
